KPTI News and Press, Karyopharm Therapeutics Inc. From 11/07/19

Biotech Pulse Biotech finally has a pulse. The improving appetite for risk has resuscitated the moribund biotechs and pharma (biopharma) groups. The Nasdaq Biotech ( IBB ) and the S&P Biotech ( XBI ) indexes have begun their advance from their year-to-date lows recorded earlier in Octo...

-- Updated Results from the Pomalyst® and Kyprolis® Arms of the Phase 1b/2 STOMP Study Evaluating Selinexor in Combination with Other Approved Myeloma Therapies in Relapsed or Refractory Multiple Myeloma to be Highlighted -- -- Other Key Presentations Include New Data from t...

"Sloth makes all things difficult, but industry all easy; and he that riseth late must trot all day, and shall scarce overtake his business at night; while laziness travels so slowly, that poverty soon overtakes him .”― Benjamin Franklin Karyopharm Therapeutics ( KPTI ) re...

Image source: The Motley Fool. Karyopharm Therapeutics Inc   (NASDAQ: KPTI) Q3 2019 Earnings Call Nov 4, 2019 , 8:30 a.m. ET Operator Continue reading

Karyopharm Therapeutics Inc. (KPTI) Q3 2019 Results Earnings Conference Call November 04, 2019, 08:30 AM ET Company Participants Ian Karp - Vice President, Investor and Public Relations Michael Kauffman - Chief Executive Officer Sharon Shacham - President and Chief Scientific Off...

Camber Energy (NYSEMKT: CEI ) +53% . More news on: Camber Energy, Inc., Wright Medical Group N.V., Enlivex Therapeutics Ltd., Stocks on the move, Read more ...

The following slide deck was published by Karyopharm Therapeutics Inc. in conjunction with their 2019 Q3 earnings Read more ...

Karyopharm Therapeutics (NASDAQ: KPTI ): Q3 GAAP EPS of -$0.67 beats by $0.17 . Revenue of $13.15M (+5379.2% Y/Y) beats by $11.35M . Press Release More news on: Karyopharm Therapeutics Inc., Earnings news and commentary, Healthcare stocks news,

− XPOVIO Phase 2b STORM Study Results Published in The New England Journal of Medicine − − Achieved XPOVIO ® U.S. Net Product Sales of $12.8 Million with Over 500 Prescriptions Fulfilled as of September 30, 2019 – − Strengthened Balan...

NEWTON, Mass., Oct. 28, 2019 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an oncology-focused pharmaceutical company, today announced that it will report third quarter 2019 financial results on Monday, November 4, 2019. Karyopharm's management team will host a conference ...